Illustrative image – not actual.Sterling Biotech has plans to invest Rs.180 crore in expansion and backward integration.
The expansion – the third by the company in the last five years – envisages enhancing the capacity for pharmaceutical grade gelatin from the current 6,000 tonnes per annum to 14,200 tonnes per annum, at Vadodara in Gujarat.
The expanded capacity, set to become operational within the next 18 months, will primarily cater to the markets in Europe and USA. To meet the export requirements, Sterling has already received a Certificate of Suitability (CoS) from the European Directorate for the Quality of Medicine, ISO-14000 from Norsk Veritas and HACCP.
The scheme is proposed to be funded through a Global Depository Receipt (GDR) issue, besides internal accruals and loans.
Further, as a backward integration measure, Sterling is exploring the option of setting up a bone mill plant. This move is expected to substantially reduce raw material costs.
